Brought to you by 
ImmunoGen adds Merck's Keytruda to its ovarian cancer trials
14 Oct 2021
Executive Summary
ImmunoGen Inc. and Merck & Co. Inc. entered into an trial collaboration to investigate the combination of Merck's marketed immunotherapy Keytruda (pembrolizumab) with Immunogen's mirvetuximab soravtansine for ovarian cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ImmunoGen adds Merck's Keytruda to its ovarian cancer trials
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice